FIBROGEN INC - COMMON

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

05 فبراير 2024 04:00:00 بحسب Nasdaq GlobeNewswire

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

25 يناير 2024 04:00:00 بحسب Nasdaq GlobeNewswire

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

09 ديسمبر 2023 14:02:00 بحسب Nasdaq GlobeNewswire

FibroGen Reports Third Quarter 2023 Financial Results

06 نوفمبر 2023 13:01:00 بحسب Nasdaq GlobeNewswire

FibroGen to Report Third Quarter 2023 Financial Results

23 أكتوبر 2023 04:00:00 بحسب Nasdaq GlobeNewswire

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

29 أغسطس 2023 13:15:00 بحسب Nasdaq GlobeNewswire

FibroGen Reports Second Quarter 2023 Financial Results

07 أغسطس 2023 13:01:00 بحسب Nasdaq GlobeNewswire

FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

26 يونيو 2023 04:04:00 بحسب Nasdaq GlobeNewswire

FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

07 يونيو 2023 03:55:00 بحسب Nasdaq GlobeNewswire

FibroGen to Present at Jefferies Global Healthcare Conference

06 يونيو 2023 13:01:00 بحسب Nasdaq GlobeNewswire

FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

18 مايو 2023 04:30:00 بحسب Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2023 Financial Results

08 مايو 2023 13:01:00 بحسب Nasdaq GlobeNewswire

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

08 مايو 2023 13:00:00 بحسب Nasdaq GlobeNewswire

FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)

05 مايو 2023 04:30:00 بحسب Nasdaq GlobeNewswire

FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value

01 مايو 2023 04:00:00 بحسب Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2023 Financial Results

24 أبريل 2023 04:00:00 بحسب Nasdaq GlobeNewswire

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

03 أبريل 2023 04:00:00 بحسب Nasdaq GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results

27 فبراير 2023 13:01:00 بحسب Nasdaq GlobeNewswire

FibroGen to Present at Cowen’s 43rd Annual Health Care Conference

27 فبراير 2023 04:00:00 بحسب Nasdaq GlobeNewswire

FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results

17 فبراير 2023 04:00:00 بحسب Nasdaq GlobeNewswire